[Therapeutic indications targeting etiology. (With the exception of primary progressive forms)].
On the subject of the treatment of Multiple Sclerosis, JM Charcot stated in 1877 that "the time has not yet come when such a subject can be seriously considered". Fortunately such point of view is no more up to date. This chapter will review the available treatment for relapsing-remitting and secondary progressive Multiple Sclerosis. The immunosuppressive drugs and steroids have been used for many years. Immunomodulation appeared more recently. A review of the evidence on the use of those drugs will be performed.
Brassat
D
D
Fédération de Neurologie, Hopital Purpan, place du Dr Baylac, 31059 Toulouse.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents
Indications thérapeutiques à visée étiologique. (A l'exception des formes primitivement progressives).